Bio

Bio


Dr. Hall graduated summa cum laude from UC Santa Cruz with a Bachelor of Science in Neuroscience and Behavior and received his MD from the Keck School of Medicine of USC. He completed an internal medicine internship at Santa Clara Valley Medical Center. He went on to train in neurology at Stanford University where he also completed a clinical fellowship in behavioral neurology.

Dr. Hall’s clinical expertise includes mild cognitive impairment, dementia with Lewy bodies, Alzheimer’s disease, primary progressive aphasia, posterior cortical atrophy, frontotemporal dementia and vascular cognitive impairment.

Dr. Hall’s non-clinical time is spent studying novel imaging techniques for neurodegenerative disorders, participating in Alzheimer’s disease clinical trials and working with the Stanford Alzheimer’s Disease Research Center.

Clinical Focus


  • Neurology
  • Mild cognitive impairment
  • Dementia
  • Alzheimer's disease
  • Dementia with Lewy bodies
  • Vascular cognitive impairment

Academic Appointments


Professional Education


  • Board Certification: Behavioral Neurology and Neuropsychiatry, United Council for Neurologic Subspecialties (2018)
  • Medical Education: University of Southern California Keck School of Medicine Registrar (2013) CA
  • Fellowship: Stanford University Behavioral Neurology Fellowship (2018) CA
  • Board Certification: Neurology, American Board of Psychiatry and Neurology (2017)
  • Residency: Stanford University Neurology Residency (2017) CA
  • Internship: Santa Clara Valley Medical Center Internal Medicine Residency (2014) CA

Publications

All Publications


  • Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases. European journal of nuclear medicine and molecular imaging Mormino, E. C., Toueg, T. N., Azevedo, C., Castillo, J. B., Guo, W., Nadiadwala, A., Corso, N. K., Hall, J. N., Fan, A., Trelle, A. N., Harrison, M. B., Hunt, M. P., Sha, S. J., Deutsch, G., James, M., Fredericks, C. A., Koran, M. E., Zeineh, M., Poston, K., Greicius, M. D., Khalighi, M., Davidzon, G. A., Shen, B., Zaharchuk, G., Wagner, A. D., Chin, F. T. 2020

    Abstract

    In vivo measurement of the spatial distribution of neurofibrillary tangle pathology is critical for early diagnosis and disease monitoring of Alzheimer's disease (AD).Forty-nine participants were scanned with 18F-PI-2620 PET to examine the distribution of this novel PET ligand throughout the course of AD: 36 older healthy controls (HC) (age range 61 to 86), 11 beta-amyloid+ (Aβ+) participants with cognitive impairment (CI; clinical diagnosis of either mild cognitive impairment or AD dementia, age range 57 to 86), and 2 participants with semantic variant primary progressive aphasia (svPPA, age 66 and 78). Group differences in brain regions relevant in AD (medial temporal lobe, posterior cingulate cortex, and lateral parietal cortex) were examined using standardized uptake value ratios (SUVRs) normalized to the inferior gray matter of the cerebellum.SUVRs in target regions were relatively stable 60 to 90 min post-injection, with the exception of very high binders who continued to show increases over time. Robust elevations in 18F-PI-2620 were observed between HC and Aβ+ CI across all AD regions. Within the HC group, older age was associated with subtle elevations in target regions. Mildly elevated focal uptake was observed in the anterior temporal pole in one svPPA patient.Preliminary results suggest strong differences in the medial temporal lobe and cortical regions known to be impacted in AD using 18F-PI-2620 in patients along the AD trajectory. This work confirms that 18F-PI-2620 holds promise as a tool to visualize tau aggregations in AD.

    View details for DOI 10.1007/s00259-020-04923-7

    View details for PubMedID 32572562

Latest information on COVID-19